Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075832 | 0.94 | GAA (0.64) | GAALMNAFFAR1FFAR4MEN1 | |
| SCHEMBL9208372 | 0.82 | GAA (0.89) | GAALMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4079697 | 0.82 | SMN1; SMN2 (0.75) | GAALMNAMEN1KMT2ANPC1 | |
| SCHEMBL17372432 | 0.82 | NPC1 (0.57) | GAALMNAFFAR1FFAR4MEN1 | |
| SCHEMBL24499495 | 0.80 | NPC1 (0.61) | LMNAFFAR1FFAR4NPC1MAPT | |
| SCHEMBL6290205 | 0.80 | NPC1 (0.61) | LMNAFFAR1FFAR4NPC1MAPT | |
| SCHEMBL6290206 | 0.80 | NPC1 (0.61) | LMNAFFAR1FFAR4NPC1MAPT | |
| SCHEMBL13206791 | 0.79 | TPSAB1 (0.62) | GAAMEN1KMT2ATSHRTPSAB1 | |
| SCHEMBL13206789 | 0.79 | TPSAB1 (0.62) | GAAMEN1KMT2ATSHRTPSAB1 | |
| SCHEMBL1750050 | 0.79 | CYP1A2 (0.58) | LMNAFFAR1FFAR4KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | GAA 20/4885LMNA 1995/4885FFAR1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.